{
  "cik": 1672619,
  "cik_padded": "0001672619",
  "entityName": "Enliven Therapeutics, Inc.",
  "fiscal_years": [
    {
      "accn": "0001193125-26-088232",
      "filed": "2026-03-03",
      "fiscal_year": 2025,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 158000.0,
        "cash": 98896000.0,
        "eps_diluted": -1.83,
        "free_cash_flow": -70459000.0,
        "net_income": -103694000.0,
        "operating_cash_flow": -70301000.0,
        "operating_income": -119658000.0,
        "stockholders_equity": 459600000.0,
        "total_assets": 476168000.0,
        "total_liabilities": 16568000.0
      },
      "period_end": "2025-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.036048738033072236,
        "roa_avg2y": -0.25861174569288015,
        "roa_period_end": -0.21776767863443156,
        "roe_avg2y": -0.26952933607990176,
        "roe_period_end": -0.22561792863359442
      }
    },
    {
      "accn": "0001193125-26-088232",
      "filed": "2026-03-03",
      "fiscal_year": 2024,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 44000.0,
        "cash": 124117000.0,
        "eps_diluted": -1.89,
        "free_cash_flow": -73236000.0,
        "net_income": -89024000.0,
        "operating_cash_flow": -73192000.0,
        "operating_income": -104554000.0,
        "stockholders_equity": 309845000.0,
        "total_assets": 325760000.0,
        "total_liabilities": 15915000.0
      },
      "period_end": "2024-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.051364391873356036,
        "roa_avg2y": -0.29792495988300394,
        "roa_period_end": -0.2732809430255403,
        "roe_avg2y": -0.3203736925349662,
        "roe_period_end": -0.28731785247462444
      }
    },
    {
      "accn": "0001193125-26-088232",
      "filed": "2026-03-03",
      "fiscal_year": 2023,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 149000.0,
        "cash": 100141000.0,
        "eps_diluted": -2.01,
        "free_cash_flow": -61418000.0,
        "net_income": -71584000.0,
        "operating_cash_flow": -61269000.0,
        "operating_income": -83529000.0,
        "stockholders_equity": 245906000.0,
        "total_assets": 271867000.0,
        "total_liabilities": 25961000.0
      },
      "period_end": "2023-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.10557286117459518,
        "roa_avg2y": -0.403102783213436,
        "roa_period_end": -0.26330521909610216,
        "roe_avg2y": -0.8467420940259403,
        "roe_period_end": -0.2911031044382813
      }
    },
    {
      "accn": "0000950170-25-038758",
      "filed": "2025-03-13",
      "fiscal_year": 2022,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 612000.0,
        "cash": 75536000.0,
        "eps_diluted": -12.05,
        "free_cash_flow": -32689000.0,
        "net_income": -37662000.0,
        "operating_cash_flow": -32077000.0,
        "operating_income": -38791000.0,
        "stockholders_equity": -76825000.0,
        "total_assets": 83298000.0,
        "total_liabilities": 10374000.0
      },
      "period_end": "2022-12-31",
      "ratio_units": {
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio"
      },
      "ratios": {
        "roa_avg2y": -0.4256940048829008,
        "roa_period_end": -0.4521357055391486,
        "roe_avg2y": 0.6292101042502005
      }
    },
    {
      "accn": "0000950170-24-031495",
      "filed": "2024-03-14",
      "fiscal_year": 2021,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 12000.0,
        "cash": 48309000.0,
        "eps_diluted": -2.37,
        "free_cash_flow": -46783000.0,
        "net_income": -51384000.0,
        "operating_cash_flow": -46771000.0,
        "operating_income": -51442000.0,
        "stockholders_equity": -42887000.0,
        "total_assets": 93646000.0,
        "total_liabilities": 7616000.0
      },
      "period_end": "2021-12-31",
      "ratio_units": {
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio"
      },
      "ratios": {
        "roa_avg2y": -0.5570443606088201,
        "roa_period_end": -0.5487046964098841,
        "roe_avg2y": -2.4734764609608164
      }
    },
    {
      "accn": "0001564590-23-001729",
      "filed": "2023-02-10",
      "fiscal_year": 2020,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 18000.0,
        "cash": 47698000.0,
        "free_cash_flow": -37416000.0,
        "net_income": -41360000.0,
        "operating_cash_flow": -37398000.0,
        "operating_income": -41698000.0,
        "stockholders_equity": 84435000.0,
        "total_assets": 90842000.0,
        "total_liabilities": 6407000.0
      },
      "period_end": "2020-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.07588085509563569,
        "roa_avg2y": -0.6663444498147253,
        "roa_period_end": -0.45529600845423923,
        "roe_avg2y": -2.324444319554894,
        "roe_period_end": -0.4898442588973767
      }
    },
    {
      "accn": "0001564590-22-010216",
      "filed": "2022-03-15",
      "fiscal_year": 2019,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 140000.0,
        "cash": 4936000.0,
        "free_cash_flow": -22017000.0,
        "net_income": -23463000.0,
        "operating_cash_flow": -21877000.0,
        "operating_income": -24116000.0,
        "stockholders_equity": -48848000.0,
        "total_assets": 33298000.0,
        "total_liabilities": 4382000.0
      },
      "period_end": "2019-12-31",
      "ratio_units": {
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio"
      },
      "ratios": {
        "roa_period_end": -0.7046369151300378,
        "roe_avg2y": 0.624314831568304
      }
    },
    {
      "accn": "0001564590-21-011098",
      "filed": "2021-03-05",
      "fiscal_year": 2018,
      "form": "10-K",
      "fundamental_units": {
        "stockholders_equity": "USD"
      },
      "fundamentals": {
        "stockholders_equity": -26316000.0
      },
      "period_end": "2018-12-31",
      "ratios": {}
    }
  ],
  "latest_filing": {
    "accn": "0001193125-26-088232",
    "filed": "2026-03-03",
    "form": "10-K"
  },
  "note": "Static grepcent export of verified SEC companyfacts-derived values. Monetary values are raw reported units from grepcent's resolved facts; no scaling and no FX conversion. Capex, dividends, and buybacks are reported as positive outflow magnitudes. ROE/ROA include both period-end basis (site-consistent) and average-of-two-years basis where the prior-year denominator exists.",
  "schema_version": "1",
  "sic": "2834",
  "sic_description": "Pharmaceutical Preparations",
  "source_urls": {
    "sec_companyfacts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001672619.json",
    "sec_submissions": "https://data.sec.gov/submissions/CIK0001672619.json"
  },
  "ticker": "ELVN"
}